Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes
Brief Summary: The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (GnRH) antagonist vs. an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization (IVF) outcome in patients stimulated with recombinant follicle-stimulating hormone (FSH) and human chorionic gonadotrophin (hCG) microdose.


Options:
A: Inclusion Criteria:

* females of infertile couples for whom COS and IVF or ICSI is indicated
* body mass index between 18 and 29 kg/m2
* willing and able to give written informed consent.

Exclusion Criteria:

* More than three previous COS cycles for assisted reproduction since last established ongoing pregnancy (if applicable)
* History of no or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment
* Less than 2 ovaries or any other ovarian abnormality including endometrioma
* Presence of unilateral or bilateral hydrosalpinx
* Any ovarian and/or abdominal abnormality that would interfere with adequate ultrasound investigation of at least one ovary
* History of or current polycystic ovary syndrome (PCOS)
* History of/or current endocrine abnormality
* Any clinically relevant hormone value outside the reference range during the early follicular phase
* Any clinically significant abnormal laboratory value
* Hypertension or currently treated hypertension
* Recent history of current epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary disease
* Alcohol or drug abuse, or history thereof
* Current serious allergic symptoms
* Abnormal cervical smear
* Known hypersensitivity to gonadotropin releasing hormone (GnRH) or its analogs;
* Contra-indications for the use of gonadotropins
* Use of hormonal preparations within 1 month prior to the date of signing consent;
* Administration of any investigational product within 3 months prior to screening.
B: Inclusion Criteria:

* women of good physical and mental health
* under 37 years old, with regular menstrual cycles of 25-35 days
* normal basal FSH and LH levels
* BMI less than 30 kg/m2
* presence of both ovaries and intact uterus
* absence of polycystic ovaries
* endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases
* all patients signed a written informed consent form
* no patient had received any hormone therapy for at least 60 days preceding the study.
C: Inclusion Criteria:

* IVF treatment in the following indications: Male, Mechanical, Unexplained
* Age\<38 years
* Treatment Cycle number 1-4

Exclusion Criteria:

* Ovulatory disorder as an indication for IVF
* Repeated failure in previous IVF treatments (\> than 4 cycles)
* Sperm used for treatment was retrieved by surgical procedure
D: Inclusion Criteria:

* Puregon® (recFSH)/Orgalutran® group:

  * Women with a pregnancy of \>= 16 weeks after Puregon® /Orgalutran® treatment for IVF or ICSI and ET of fresh embryos. Treatment is defined as having had at least one injection of Orgalutran®.
  * Women between 18 and 39 years of age (inclusive) at the day of hCG.
  * Women who are able and willing to sign informed consent.

Controls

* Infants (gestational age \>=16 weeks) of women pregnant after COH using a GnRH agonist in a long protocol for IVF or ICSI and ET of fresh embryos.
* Infants of women between 18 and 39 years of age (inclusive) at the day of hCG.
* The most recent 1000 infants delivered prior to January 1, 2001.

Exclusion Criteria:

* None

Answer: B